HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Executive Summary

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

You may also be interested in...



Thinking About Entering The EU CBD Market? Some Food For Thought

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

With ‘CBD HQ,' Vitamin Shoppe Reflects US Industry Confidence In Cannabidiols Market's Future

Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.

Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance

A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel